GuidelineDiabetes care2026
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.
Guideline in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Trial
- Cardiovascular risk equations in type 1 diabetes: from generic models to personalized prediction.Annals of medicine · 2026Review
- Comparing incidence of heart failure in individuals with enlarged cardiac chambers versus diabetes.American journal of preventive cardiology · 2026Article
- Type 1 diabetes and cardiovascular medicine.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Lichen-Derived Bioactive Compounds in Diabetes and Cardiovascular Risk: Experimental Evidence, Mechanisms, and Translational Challenges.Biomedicines · 2026Review
- Multidomain Cardiorenal-Metabolic Abnormalities Despite HbA1c <7% in Type 2 Diabetes: A Real-World Observational Study.Diseases (Basel, Switzerland) · 2026Article
- Low Serum C-Peptide and Albuminuria Severity in Type 2 Diabetes Mellitus: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Association Between the Triglyceride-to-HDL Cholesterol Ratio and Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Real-World Retrospective Study.Biomedicines · 2026Article
- Type 2 Diabetes, Visceral Adiposity, and Carotid Intima-Media Thickness in Hospitalized Adults: A Retrospective Cross-Sectional Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care.Cardiology and therapy · 2026Review
- Asymmetric Dimethylarginine as an Integrative Biomarker of Endothelial, Cardiometabolic and Hepatic Dysfunction in Stable Coronary Artery Disease.Biomedicines · 2026Article
- Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence.Medicina (Kaunas, Lithuania) · 2026Review
- Review
- Evolving Heart Failure Profiles in Quebec from 1998-2021: Insights from the Vision C+ Database.CJC open · 2026Article
- Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.Journal of managed care & specialty pharmacy · 2026Article
- MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.Current hypertension reports · 2026Review
- Long-Term Associations of a Mobile-Based Chronic Disease Management Program With Employee Health: Four-Year Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- Cardiovascular Risk Factor Control Among Young Adults With Diabetes in the United States Between 2013 and 2023.Journal of the American Heart Association · 2026Article
- Molecular Pathways of Cardiometabolic Residual Risk in Type 2 Diabetes: Insulin Resistance, Metaflammation, and Liver-Kidney-Vascular Crosstalk.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.